Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relapse risk of lupus-related serositis according to immunosuppressive therapy: a national real-world study.

RMD open·2026
Same author

Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series.

Annals of the rheumatic diseases·2026
Same author

Scaling up X-ray holographic nanotomography for neuronal tissue imaging.

Biomedical optics express·2026
Same author

Comparison of disease severity and activity between juvenile- and adult-onset dermatomyositis: a multicentre cohort study.

Rheumatology (Oxford, England)·2026
Same author

Anyon Braiding on the Single Edge of a Fractional Quantum Hall State.

Physical review letters·2025
Same author

Corrigendum to "Investigation of the binding mode of clobenprobit at CXCR4 and development of novel anti-inflammatory compounds with enhanced activity and minimal antagonist effects" [Molecular Pharmacology 107 (2025) 100055].

Molecular pharmacology·2025

Related Experiment Video

Updated: Jun 27, 2026

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

The antiphospholipid syndrome.

Jean-Louis Pasquali1, Vincent Poindron, Anne-Sophie Korganow

  • 1Clinical Immunology Department, Nouvel Hopital Civil, Hopitaux Universitaires de Strasbourg, Université de Strasbourg and INSERM, U737, 67091 Strasbourg, France. jean-louis.pasquali@chru-strasbourg.fr

Best Practice & Research. Clinical Rheumatology
|November 26, 2008
PubMed
Summary
This summary is machine-generated.

Antiphospholipid syndrome is an autoimmune disorder causing blood clots and pregnancy issues. It is linked to specific autoantibodies targeting protein-phospholipid complexes.

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Related Experiment Videos

Last Updated: Jun 27, 2026

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Area of Science:

  • Immunology
  • Rheumatology
  • Hematology

Background:

  • Antiphospholipid syndrome (APS) is an acquired autoimmune disorder.
  • Characterized by recurrent thrombosis (arterial/venous) and/or pregnancy complications.
  • Associated with persistent serum autoantibodies.

Purpose of the Study:

  • To define the key features of antiphospholipid syndrome.
  • To identify the specific autoantibodies involved in APS pathogenesis.
  • To elucidate the targets of these autoantibodies.

Main Methods:

  • Serological testing for autoantibodies.
  • Clinical assessment for thrombotic events and pregnancy outcomes.
  • Immunological assays to characterize antibody targets.

Main Results:

  • The presence of lupus anticoagulant and anticardiolipin antibodies is a hallmark of APS.
  • These autoantibodies are primarily directed against complexes of proteins and anionic phospholipids.
  • A strong association exists between these autoantibodies and clinical manifestations of APS.

Conclusions:

  • Antiphospholipid syndrome is characterized by specific autoantibodies.
  • These antibodies target protein-phospholipid complexes, driving thrombosis and pregnancy morbidity.
  • Diagnosis relies on clinical criteria and laboratory confirmation of autoantibodies.